<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111968</url>
  </required_header>
  <id_info>
    <org_study_id>BUTVAC - Influenza A (H1N1)</org_study_id>
    <nct_id>NCT01111968</nct_id>
  </id_info>
  <brief_title>Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines</brief_title>
  <official_title>Evaluation of Safety, Tolerability and Immunogenicity of Adjuvanted Candidate Vaccines Against Pandemic Influenza A (H1N1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butantan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario da USP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butantan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase I study to evaluate the safety, tolerability and immunogenicity
      of nine adjuvanted candidate vaccines against pandemic influenza A (H1N1) virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The candidate vaccines are produced by Butantan institute - Sao Paulo, Brazil
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay</measure>
    <time_frame>21 days after each vaccination</time_frame>
    <description>Volunteers will receive two doses of vaccine,21 days apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>30 minutes and 72 hours after vaccination</time_frame>
    <description>Evaluation of local and systemic adverse effects throught the study period</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>pandemic vaccine 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7,5µg of A/H1N1 with Al(OH)3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3,75µg of A/H1N1 with Al(OH)3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pandemic vaccine 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15µg of A/H1N1 with no adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group 14</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic vaccine 1</intervention_name>
    <description>7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3</description>
    <arm_group_label>pandemic vaccine 1</arm_group_label>
    <other_name>vaccine group C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic vaccine 2</intervention_name>
    <description>3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3</description>
    <arm_group_label>pandemic vaccine 2</arm_group_label>
    <other_name>vaccine group I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic vaccine 5</intervention_name>
    <description>7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion</description>
    <arm_group_label>pandemic vaccine 5</arm_group_label>
    <other_name>vaccine group N</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic vaccine 6</intervention_name>
    <description>3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion</description>
    <arm_group_label>pandemic vaccine 6</arm_group_label>
    <other_name>vaccine group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic vaccine 9</intervention_name>
    <description>7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion</description>
    <arm_group_label>pandemic vaccine 9</arm_group_label>
    <other_name>vaccine group F</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandemic vaccine 10</intervention_name>
    <description>3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion</description>
    <arm_group_label>pandemic vaccine 10</arm_group_label>
    <other_name>vaccine group L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandmeic vaccine 11</intervention_name>
    <description>7,5µg of A/H1N1 with Al(OH)3</description>
    <arm_group_label>pandemic vaccine 11</arm_group_label>
    <other_name>vaccine group E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandmeic vaccine 12</intervention_name>
    <description>3,75µg of A/H1N1 with Al(OH)3</description>
    <arm_group_label>pandemic vaccine 12</arm_group_label>
    <other_name>vaccine group K</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pandmic vaccine 13</intervention_name>
    <description>15µg of A/H1N1 with no adjuvant</description>
    <arm_group_label>pandemic vaccine 13</arm_group_label>
    <other_name>vaccine group H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo group 14</intervention_name>
    <description>All elements of the vaccine but antigen and adjuvant</description>
    <arm_group_label>placebo group 14</arm_group_label>
    <other_name>vaccine group B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health adults of both genders

          -  Age ≥ 18 ≤ 50 years

          -  Able to understand every required study procedure

          -  Female volunteers should agree to take an acceptable contraceptive method Menopause is
             characterized by absence of menstrual flux for two consective years

          -  Normal values for pre-stablished laboratory assays

          -  Accpetance to participate and sign the consent form

        Exclusion Criteria:

          -  Any chronic condition

          -  Be on immunossupressive or stimulant therapy

          -  Have egg alergy

          -  Have past history of alergy to sazonal influenza vaccine

          -  Have received another inactivated vaccine within the prior 2 weeks or a live vaccine
             in the past four weeks to his/her participation in the study

          -  Acute infectious disease during seven days prior vaccination

          -  Female on breasthfeeding

          -  Confirmed prior infection by pandemic influenza A

          -  Participation in another clinical trial in the last 6 months

          -  Any other condition identified by the principal investigator which is considered not
             safe for enrollment of the volunteer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucia MA Campos, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children´s Institute - School of Medicine of University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Pesquisa Clinica do Instituto da Criança do hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Hospital Universitário da USP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05508000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>pandemic influenza A</keyword>
  <keyword>adjuvant</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

